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Summary
 
In this report, we establish a regulatory role of natural killer (NK) cells in experimental autoim-
mune encephalomyelitis (EAE), a prototype T helper cell type 1 (Th1)-mediated disease. Ac-
tive sensitization of C57BL/6 (B6) mice with the myelin oligodendrocyte glycoprotein
(MOG)
 
35-55
 
 peptide induces a mild form of monophasic EAE. When mice were deprived of
NK cells by antibody treatment before immunization, they developed a more serious form of
EAE associated with relapse. Aggravation of EAE by NK cell deletion was also seen in 
 
b
 
2-
microglobulin
 
2
 
/
 
2
 
 (
 
b
 
2m
 
2
 
/
 
2
 
) mice, indicating that NK cells can play a regulatory role in a man-
ner independent of CD8
 
1
 
 T cells or NK1.1
 
1
 
 T cells (NK–T cells). The disease enhancement
was associated with augmentation of T cell proliferation and production of Th1 cytokines in
response to MOG
 
35-55
 
. EAE passively induced by the MOG
 
35-55
 
-specific T cell line was also
enhanced by NK cell deletion in B6, 
 
b
 
2m
 
2
 
/
 
2
 
, and recombination activation gene 2 (RAG-
2)
 
2
 
/
 
2
 
 mice, indicating that the regulation by NK cells can be independent of T, B, or NK–T
cells. We further showed that NK cells inhibit T cell proliferation triggered by antigen or cy-
tokine stimulation. Taken together, we conclude that NK cells are an important regulator for
EAE in both induction and effector phases.
 
E
 
xperimental autoimmune encephalomyelitis (EAE)
 
1
 
 is
a prototype autoimmune disease induced in laboratory
animals, bearing significant similarities to multiple sclerosis
in clinical and pathological aspects (1, 2). EAE is mediated
by CD4
 
1
 
 T cells that recognize peptides derived from en-
cephalitogenic proteins of the central nervous system in as-
sociation with MHC class II molecules. The encephalito-
genic T cells in EAE produce T helper cell type 1 (Th1)
cytokines such as IL-2, IFN-
 
g
 
, and TNF-
 
a
 
.
In principle, EAE induced by active challenge with en-
cephalitogenic peptides represent monophasic or polyphasic
clinical courses in which ascending paralysis is usually fol-
lowed by spontaneous recovery. The recovery process
probably depends on cellular interactions between enceph-
alitogenic T cells and regulatory cells. In support of this
concept, previous studies revealed that 
 
a
 
/
 
b
 
 T cells express-
ing CD4
 
1
 
 (3, 4), CD8
 
1
 
 (5–7), or CD4
 
2
 
CD8
 
2
 
 (8, 9) phe-
notype can play a regulatory role in EAE. More recently,
B cells (10) and 
 
g
 
/
 
d
 
 T cells (11) have also been identified as
putative regulatory elements in EAE. Although encephalito-
genic peptides (4) or TCR peptides (3, 9) in association with
MHC molecules are recognized as the receptor ligands for
some regulatory T cells, little is known about how other
regulatory cells are triggered.
In this study, we examined whether NK cells could serve
as a regulatory element in EAE. The possible role of NK
cells in immunoregulation has been suggested in a number
of studies (12–17). However, most of the previous works
have focused on the role of NK cells in the immune re-
sponse to foreign microbes, and did not investigate their
role in the regulation of autoimmune response or autoim-
mune disease. Furthermore, the experimental results have
not always been conclusive in proving the regulatory role
of NK cells. In fact, early studies (12, 14) used antiasialo
GM1 sera for NK cell deletion which can damage mac-
rophages (18) or T cells (19), and the others (13, 15–17)
did not distinguish NK cells from NK1.1
 
1
 
 T cells (NK–T
cells) (20–22), a novel lymphocyte population that produces
a large amount of IL-4 after TCR ligation (23). Because
the decline of NK–T cells has been seen in the develop-
ment of animal and human autoimmune diseases (24, 25)
 
1
 
Abbreviations used in this paper:
 
 
 
b
 
2m; 
 
b
 
2-microglobulin; EAE, experimen-
tal autoimmune encephalomyelitis; MOG, myelin oligodendrocyte gly-
coprotein; PT, pertussis toxin; RAG, recombination activation gene.
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and in vivo deletion of NK–T cells can enhance the disease
development (24), it is crucial to distinguish NK and NK–T
cells in consideration for their regulatory functions.
To overcome the problems inherent in the previous stud-
ies, we selected a model of EAE induced in C57/BL6 (B6)
with myelin oligodendrocyte glycoprotein (MOG)
 
35-55
 
 pep-
tide (26). The B6 model is particularly useful, since the
method of in vivo NK cell deletion is established and vari-
ous gene knockout mice are available with the B6 back-
ground (27–29). We found that NK cell deletion in vivo
results in enhancement of EAE in wild-type B6 mice. Us-
ing gene knockout mutant mice lacking 
 
b
 
2-microglobulin
(
 
b
 
2-m)
 
2
 
/
 
2
 
 (27) or recombination activation gene (RAG)-
2
 
2
 
/
 
2
 
 (28), we further proved that NK cells are qualified as a
regulatory element in passive EAE, of which function can
be independent of T, B, or NK–T cells. The results dem-
onstrate that both induction and effector phases of EAE are
subject to immunoregulation by NK cells. We also showed
that cellular transfer can effectively compete with the dis-
ease enhancement by NK cell deletion. In vitro experi-
ments indicate that the downregulation of EAE by NK
cells may arise from their inhibitory effects on T cell prolif-
eration.
 
Materials and Methods
 
Mice.
 
B6 mice were purchased from CLEA laboratory animal
corporation (Tokyo, Japan). 
 
b
 
2m
 
2
 
/
 
2
 
 (27) and IFN-
 
g
 
2
 
/
 
2
 
 (29)
mice with the B6 background were purchased from The Jackson
Laboratory (Bar Harbor, ME). RAG-2
 
2
 
/
 
2
 
 mice (28) with the B6
background were purchased from Taconic Farms, Inc. (German-
town, NY). All the mice were kept under specific pathogen-free
conditions and only female mice (8–14 wk) were used.
 
Reagents.
 
The rat MOG
 
35-55
 
 (MEVGWYRSPFSRVVH-
LYRNGK) was synthesized as previously described (30). IFA and
heat-killed 
 
Mycobacterium tuberculosis
 
 H37Ra were purchased from
Difco Laboratory (Detroit, MI). Hybridomas producing anti-NK1.1
mAb (PK136; reference 31) and isotype-matched control mAb
(M-11; specific for human melanoma cell surface antigen) were
obtained from American Type Culture Collection (Rockville, MD).
The mAbs were purified from the supernatants using Protein A
column chromatography. Anti–mouse CD3-FITC, NK1.1-PE,
IgG2a
 
b
 
 (clone 5.7), and Fc Block
 
Ô
 
Ò
 
 (anti–mouse FcR
 
g
 
 II/III
mAb) were purchased from PharMingen (San Diego, CA). The
5.7 antibody reacts specifically with mouse IgG2a of Igh-C
 
b
 
 hap-
lotype (e.g., B6, SJL/J).
 
Immunization.
 
For induction of active EAE, mice were in-
jected in the hind foodpads bilaterally with a total of 200 
 
m
 
l of
emulsion containing 200 
 
m
 
g MOG
 
35-55
 
 in IFA supplemented
with 500 
 
m
 
g of 
 
M. tuberculosis
 
. Booster immunization with an
identical emulsion was given at both sides of the flank 1 wk later.
They were intravenously injected with 500 ng of pertussis toxin
(PT) (Seikagaku Kogyo, Tokyo, Japan) in 500 
 
m
 
l of PBS shortly
after, and 48 h after first immunization. For the study of T cell re-
sponse or generation of T cell line, mice were immunized only
once with 200 
 
m
 
g MOG
 
35-55
 
 in IFA supplemented with 250 
 
m
 
g
of 
 
M. tuberculosis
 
 without subsequent injection of PT.
 
In Vivo NK Cell Deletion.
 
To deplete NK cells in vivo, mice
were intravenously injected with 500 
 
m
 
g of anti-NK1.1 mAb
(PK136) one day before first immunization with MOG
 
35-55
 
 or pas-
sive transfer of ZB-1 T cell line. Control mice were treated either
with 500 
 
m
 
g of control mAb (M-11) or PBS.
 
Culture Medium.
 
RPMI 1640 containing 5 
 
3
 
 10
 
2
 
5
 
 M 2-mer-
captoethanol (2-ME), 2 mM L-glutamine, and 100 U/
 
m
 
g/ml
penicillin/streptomycin (referred to as the basic medium) were used
after supplemented with syngeneic mouse serum or FCS alone or
with the serum and IL-2 (supernatant of Con A–stimulated rat
spleen cells).
 
T Cell Proliferative Responses.
 
To analyze the primary response,
inguinal and popliteal LN cells (4 
 
3
 
 10
 
5
 
/well) isolated from mice
immunized with MOG
 
35-55
 
 were cultured in 96-well flat-bot-
tomed plates with relevant peptides at 25 
 
m
 
g/ml in 0.2 ml of the
basic medium supplemented with 1% syngeneic serum. The cul-
tures were incubated for 72 h at 37
 
8
 
C in humidified air contain-
ing 5% CO
 
2
 
. Incorporation of [
 
3
 
H]thymidine (1 
 
m
 
Ci/well) for the
final 16 h of the incubation was counted with a beta-1205
counter (Pharmacia, Uppsala, Sweden). For assaying T cell line
proliferation, T line cells (4 
 
3
 
 10
 
4
 
/well) were cultured for 72 h in
96-well flat-bottomed plates in the presence of irradiated (3,300
rads) syngeneic spleen cells (8 
 
3
 
 10
 
5
 
/well) as APCs in 0.2 ml of
the basic medium supplemented with 5% FCS. Thymidine incor-
poration was determined as in the primary proliferation assay.
 
T Cell Line.
 
Long-term T cell lines specific for MOG
 
35-55
 
were established with our modification of the split-well tech-
nique (9). The draining LNs were removed 11 d after immuniza-
tion with MOG
 
35-55
 
 and the single-cell suspensions were prepared at
4 
 
3
 
 10
 
6
 
/ml in the basic medium supplemented with 5% FCS.
They were plated on to 96-well U-bottomed plates at 0.2 ml/
well and stimulated with 25 
 
m
 
g/ml of MOG
 
35-55
 
. The cells were
fed with the basic medium supplemented with 10% IL-2 and 10%
FCS every 3 d. On day 12, T line cells in each microwell were
individually assessed for their antigen specificity. In brief, cells
were restimulated with MOG
 
35-55
 
 (25 
 
m
 
g/ml) in another U-bot-
tomed plate in the presence of X-irradiated (3,300 rads), synge-
neic spleen cells as APCs (8 
 
3
 
 10
 
5
 
/well). Rapidly growing lines
were selected and further propagated with IL-2 in the U-bot-
tomed plates. After several cycles of alternate stimulation with
MOG
 
35-55
 
 peptide and propagation (every 10–14 d), the antigen
specificity and encephalitogenicity of the lines were determined.
The encephalitogenic T cell line ZB-1 was finally selected. The
line cells (4 
 
3
 
 10
 
4
 
/well) were stimulated with 25 
 
m
 
g/ml of
MOG
 
35-55
 
 in the presence of spleen APCs (8 
 
3
 
 10
 
5
 
/well) in the
U-bottomed plates as in the T cell line proliferation assay. 3 d
later, they were collected and injected via tail vein of recipients.
Immediately after cell transfer, 500 ng of PT was intravenously
injected. Except for RAG-2
 
2
 
/
 
2
 
 mice, all the recipients had been
irradiated with 450 rads of x rays shortly before cell transfer.
 
EAE Score.
 
After immunization or cell transfer, mice were
observed daily for clinical signs of EAE. The clinical grade was
scored as follows: 0, no clinical signs; 0.5, partial loss of tail tonic-
ity; 1, complete loss of tail tonicity; 2, flaccid tail and abnormal
gait; 3, hind leg paralysis; 4, hind leg paralysis with hind body
paresis; 5, hind and foreleg paralysis; and 6, death.
 
Cytokine ELISA.
 
11 d after immunization, the primed LN
cells (4 
 
3 105/well) were stimulated with MOG35-55 (25 mg/ml)
in 96-well U-bottomed plates in the basic medium supplemented
with 5% FCS. IFN-g, IL-2, IL-4, and IL-10 in the culture super-
natants (40 h after initiation of culture) were measured by Sandwich
ELISA using a protocol from PharMingen. TNF-a was measured
by a commercial kit (Quantikine M Mouse TNF-a Immunoas-
sayÒ) from R&D Systems (Minneapolis, MN).
Immunofluorescence Analysis. Peripheral blood or spleen cells
were treated in ACK buffer to lyse erythrocytes, washed three1679 Zhang et al.
times in PBS, and then suspended in PBS containing 0.1% BSA
and 0.01% NaN3. The cells were first incubated with Fc
BlockÔÒ for 15 min to block nonspecific binding of Ig to Fc re-
ceptor, washed in PBS, and then incubated with anti-CD3-FITC
and/or anti-NK1.1-PE for 30 min on ice. After washing, they
were suspended in PBS containing 0.5 mg/ml of propidium io-
dide (PI; Wako Pure Chemical Industries, Ltd., Osaka, Japan) and
10,000 cells were analyzed by FACSortÒ (Becton Dickinson, Moun-
tain View, CA) with CellQuestÒ software. Dead cells were ex-
cluded by gating out PI-positive cells.
Results and Discussion
Augmentation of Active EAE by NK Cell Deletion. Immu-
nization with MOG35-55 induced a mild form of mono-
phasic EAE with transient loss of tail tone in untreated B6
mice and the mice injected with PBS or control mAb (Fig.
1 A, Table 1). Although the original report (26) described
the induction of chronic, nonremitting EAE by this proto-
col, we have not seen such a serious form of EAE in any of
the mice. The difference could be due to variances in
mouse substrains or reagents used for immunization. To
know the functional role of NK cells, EAE was induced in
mice deprived of NK cells with anti-NK1.1 mAb. Control
mice were pretreated with isotype-matched control mAb
(M-11). Preparatory experiments revealed that the injec-
tion of anti-NK1.1 mAb completely deleted NK1.11 pop-
ulation from the peripheral blood and the spleen within 24 h
after antibody injection, which lasted for as long as 5 wk,
whereas control mAb induced only a mild, transient loss of
NK1.11 cells (Fig. 2). This was consistent with the descrip-
tion that the mAb is effective in depleting NK cells in vivo
(13, 15–17). In addition, we confirmed that mAbs reactive
to the allotype of the anti-NK1.1 mAb (anti-IgG2a) did
not stain spleen cells of the mice on 24 h, 72 h, 7 d, and 16 d
after injection of anti-NK1.1. This excludes the possibility
that antibody-coated NK1.11 cells may remain but cannot
be detected due to blocking of NK1.1 epitope.
The anti-NK1.1–treated mice developed EAE signifi-
cantly earlier than control mice (P ,0.001) as compared to
control mice (Fig. 1 B, Table 1). Although all the mice com-
pletely recovered from the paralysis within 10 d regardless
of the mAb treatments, only NK cell–deleted mice devel-
oped clinical relapse on days 26–29 after first immuniza-
tion. The degree of paralysis in the relapse was variable, and
mice with severe paralysis died of EAE. In summary, anti-
NK1.1 mAb treatment significantly enhanced EAE in the
mortality rate (P ,0.001) and maximum clinical grade (P
,0.01).
Augmentation of EAE in b2m2/2 Mice by NK Cell Dele-
tion. Injection of anti-NK1.1 mAb deletes both NK and
NK–T cells. Since our primary target was NK cells, exper-
imental systems were required in which involvement of
NK–T cells can be entirely excluded. Because NK–T cells,
positively selected against the CD1 molecule, are absent in
b2m2/2 mice defective for expression of CD1 (32, 33), we
used this mutant strain for further analysis. Previous studies
showed that b2m2/2 mice are susceptible to some, but not
all autoimmune diseases (34–36). We first examined whether
immunization with MOG35-55 can induce EAE in this mu-
tant. As shown in Fig. 3 A and Table 1, the mutant mice
developed monophasic EAE, of which clinical course is
comparable to that induced in wild-type B6 mice except
for significantly later onset of illness (P ,0.001). To our
knowledge, this is the first experimental proof using knock-
out mice that shows that even when class I–restricted cells
including CD81 T cells, CD42CD82 T cells, and NK–T
cells are virtually absent, there is no alteration in EAE in-
duction, spontaneous recovery, or resistance against relapses.
Figure 1. Effect of anti-NK1.1 mAb on MOG35-55 induced EAE in wild-type B6 mice. Mice were immunized two times with the MOG35-55 for EAE
induction. They were intravenously injected with PBS, 500 mg of control mAb (M-11; A), or 500 mg of anti-NK1.1 mAb (PK136; B) 1 d before first im-
munization with the MOG peptide. Clinical score of individual mice at each observation time point is shown by different marks. This is a representative
of two experiments with similar results. The result of pretreatment with PBS did not differ significantly from that with control mAb.1680 Regulation of Autoimmune Encephalomyelitis by Natural Killer Cells
Although a previous report has documented that there is a
higher frequency of EAE relapses in CD82/2 mice (6), we
have not seen any relapse in the mice lacking CD81 T cells.
Although NK cell–deleted wild-type B6 consistently re-
covered from the first episode (Fig. 1 B), b2m2/2 mice,
deprived of NK cells, developed a more serious form of
acute progressive or chronic, nonremitting EAE (Fig. 3 B).
Although the days of onset were not significantly altered,
the maximum clinical score was dramatically enhanced in
NK cell–deleted b2m2/2 as compared to control b2m2/2
(P ,0.001). Although the total mortality rate evaluated on
day 50 was not much different between NK-deleted B6 and
NK-deleted b2m2/2 (6/12 versus 12/18), the latter tended
to die at an earlier time point. If mortality rate is assessed on
day 30, NK cell–deleted b2m2/2 showed a higher rate com-
pared with NK cell–deleted wild-type mice (1/12 versus
12/18, P ,0.001). Taking it into consideration that the
clinical courses of control wild-type B6 and b2m2/2 mice
are comparable, we reason that b2m2/2 mice are more de-
pendent on regulatory NK cells than wild-type B6 in order
to compensate for the absence of class I–restricted regula-
tory cells.
Anti-NK1.1 mAb on EAE Induced in IFN-g2/2 Mice.
NK cell activity is known to be impaired in IFN-g2/2
mice (29). This information prompts us to study the effect
of NK cell deletion on EAE in this mutant strain. Interest-
ingly, the spleen in the mutant was only one-fourth the size
of that of wild-type mice. In addition, the proportion of
NK cells (NK1.11CD32 cells) in the total spleen cells was
markedly reduced (1.0% in IFN-g2/2 versus 5.0% in wild-
type), indicating that the development of NK cells is im-
paired in the mutant due to the genetic defect. As shown in
Fig. 4, IFN-g2/2 mice immunized with MOG35-55 devel-
oped monophasic EAE which is more serious and uniform
than wild-type B6 mice. Notably, pretreatment with anti-
NK1.1 mAb showed no obvious effects on the clinical
course (Fig. 4, Table 1). These results allowed us to inter-
pret that the regulation mediated by NK cells is reduced in
IFN-g2/2 mice, probably due to the decreased number as
well as impaired regulatory function of NK cells. It remains
unclear how the gene defect leads to the NK cell dysfunc-
tion.
Correlation of EAE Severity with Th1 Cytokine Produc-
tion. To know the immunological basis for the enhance-
ment of EAE by NK cell deletion, we measured the prolif-
eration of LN cells and their Th1 (IFN-g, IL-2) and Th2
(IL-4, IL-10) cytokine production in response to the MOG
peptide. As shown in Fig. 5 A, the proliferative response to
MOG35-55 was significantly enhanced with anti-NK1.1
Table 1. Effect of NK Cell Deletion on EAE Actively Induced in Wild-type B6 and Induced Mutants
Strain Treatment
Incidence
of EAE Mortality
Maximum
grade
Average
disease onset
(d)
Wild-type B6 Control 12/12 0/12 0.8 6 0.2 12.3 6 0.5
Wild-type B6 Anti-NK1.1 12/12 6/12* 4.3 6 1.8* 9.5 6 0.5‡
b2m2/2 Control 12/14 0/14 1.8 6 0.8 18.8 6 1.3
b2m2/2 Anti-NK1.1 18/18 12/18‡ 5.3 6 0.9‡ 16.1 6 2.8
IFN-g2/2 Control 6/6 5/6 5.9 6 0.2 18.2 6 1.6
IFN-g2/2 Anti-NK1.1 6/6 5/6 5.9 6 0.2 17.5 6 1.0
This table summarizes the results of actively induced EAE in wild-type B6, b2m2/2, and IFN-g2/2 mice treated with control mAb (control) or with
anti-NK1.1 mAb (anti-NK1.1). Experimental procedures are described in Materials and Methods. The mice were observed for 50 d after first immu-
nization with MOG, and incidence, mortality rate, and maximum disease grade were determined during the observation period. Data represent mean 6
SD of the total mice in each group. Significant differences raised by NK cell deletion are marked by * (P ,0.01) or ‡ (P ,0.001).
Figure 2. NK cell deletion by anti-NK1.1 mAb. B6 mice were intra-
peritoneally injected with 500 mg of control mAb (M-11; top) or 500 mg
of anti-NK1.1 mAb (PK136; bottom). On days 5, 16, and 36, the spleen
cells were stained with anti-NK1.1-PE and anti-CD3-FITC mAbs. Note
the persistent deletion of NK cells (NK1.11CD32 cells) in the total spleen
cells after anti-NK1.1 mAb treatment: 2.68–5.63% in mice treated with
control mAb versus 0.3–0.6% in mice treated with anti-NK1.1 mAb.1681 Zhang et al.
mAb treatment in both wild-type and bm2/2 mice. Pro-
duction of IFN-g by the LN cells was also enhanced by
NK deletion in vivo (Fig. 5 B). We also measured the cy-
tokine levels in the sera on day 12 after first immunization.
As shown in Table 2, the levels of IFN-g and TNF-a in
the sera were dramatically elevated in NK cell–deleted
mice compared with controls in both wild-type and b2m2/2
mice. It was interesting to note that the cytokine levels
roughly correlated with clinical severity of EAE induced in
each group of mice. In contrast, the level of IL-4 was not
altered by NK cell deletion. The association of EAE en-
hancement with enhanced production of Th1 cytokines
implied that NK cell deletion leads to the augmentation of
MOG35-55–specific Th1 induction, whereas Th2 induction
is unaltered or relatively inhibited.
Augmentation of Passive EAE by NK Cell Deletion. To learn
whether NK cells have a regulatory effect on the effector
phase of EAE as well, we studied the effect of NK cell de-
letion on EAE passively induced with the ZB-1 line. The
line T cells were CD41 and specifically recognized
MOG35-55 in the context of MHC class II (data not
shown). Adoptive transfer of 3 3 106 of the line cells did
not induce EAE in the B6 mice pretreated with PBS or
with control mAb. In contrast, mice pretreated with anti-
NK1.1 mAb developed EAE on days 8–10 after cell trans-
fer (Fig. 6 B). The clinical sign of EAE was relatively mild,
Figure 3. Effect of anti-NK1.1 mAb on MOG35-55 induced EAE in b2m2/2 mice. The mice were immunized two times with MOG35-55 peptide for
EAE induction. On the day before first immunization, control mAb (A) or anti-NK1.1 mAb (B) was intravenously injected. This is a representative of
three experiments with similar results.
Figure 4. Effect of anti-NK1.1 mAb on MOG35-55 induced EAE in IFN-g2/2 mice. The mice were immunized two times with MOG35-55 peptide for
EAE induction. 1 d before first immunization, the mice were intravenously injected with control mAb (A) or anti-NK1.1 mAb (B). The result of pretreat-
ment with PBS did not differ from results shown in A or B.1682 Regulation of Autoimmune Encephalomyelitis by Natural Killer Cells
but persisted for longer than 2 wk. The result proved that
NK1.11 cells inhibit the effector phase of EAE.
Using the same line cells, we next induced EAE in
b2m2/2 mice. To ensure the induction of disease, 107 cells
were transferred to the mutant strain. The first sign of EAE
was on days 16–17 after transfer in control mice (b2m2/2
nonpretreated or pretreated with control mAb). Although
the clinical course was variable, none of the mice died of
EAE in the observation period 50 d after cell transfer (Fig.
7 A). In contrast, NK cell–deleted b2m2/2 mice developed
earlier onset of hyperacute EAE and all the mice died
within 1 wk after onset (Fig. 7 B) proving that the regula-
tory role of NK cells in passive EAE can be independent of
NK–T cells or CD81 T cells.
Next we injected the line cells into RAG-22/2 mice,
which lack T, B, and NK–T cells due to the defect in the
recombination machinery. Transfer of 107 or 3 3 106 cells
induced a hyperacute, lethal form of EAE in untreated
RAG-22/2 mice (data not shown). This indicates that the
RAG-22/2 mice are more prone to passive EAE than wild-
type or b2m2/2 mice, probably due to the absence of reg-
ulatory cells bearing clonotypic receptors. In contrast,
when the number of transferred cells was reduced to 5 3
105, EAE was not induced in control RAG-22/2 mice.
However, if NK cells were deleted in vivo, the same num-
ber of cells induced hyperacute EAE within 5–6 d after cell
transfer (Fig. 8 B). Notably, this lethal disease was com-
pletely prevented by transfer of 2 3 107 spleen cells of nor-
mal RAG-22/2 mice, which contain 4 3 106 NK cells
(Fig. 8 C). In contrast, the same number of spleen cells of
RAG-22/2 mice deprived of NK cells with anti-NK1.1
Figure 5. Effect of NK cell deletion on T cell response to MOG35-55.
(A) LN cell proliferative response. 11 d after immunization with MOG35-55,
draining LN cells were prepared and their proliferative responses to
MOG35-55, PLP136-150 (PLP), and rat myelin basic protein89-101 (MBP) (ref-
erence 9) were assayed by a standard method. 1 d before immunization,
mice were injected intravenously either with control mAb or with anti-
NK1.1 mAb. Data represent mean 6 SD of the mean cpm obtained by
triplicate cultures in four independent experiments. Each column shows
the data of wild-type B6 mice pretreated with control M-11 mAb
(B6,control), B6 pretreated with anti-NK1.1 mAb (B6,anti-NK1.1),
b2m2/2 mice pretreated with control M-11 mAb (b2m2/2, control), and
b2m2/2 mice pretreated with anti-NK1.1 mAb (b2m2/2, anti-NK1.1).
(B) IFN-g production by LN cells. 11 d after immunization with
Table 2. Cytokine Levels in the Sera of Mice on Day 12 after Immunization
Strain Treatment IFN-g TNF-a IL-4
Wild-type B6 – 46.8 6 2.2 46.3 6 2.8 62.3 6 2.3
Wild-type B6 Control 80.2 6 2.8 48.2 6 1.8 65.4 6 4.1
Wild-type B6 Anti-NK1.1 348.6 6 15.1‡ 114.7 6 4.3‡ 66.8 6 3.4
b2m2/2 – 114.4 6 5.1 118.2 6 6.9 79.6 6 2.7
b2m2/2 Control 263.7 6 17.6 117.3 6 11.0 67.9 6 3.6
b2m2/2 Anti-NK1.1 1043.7 6 28.7‡ 283.8 6 8.3* 72.1 6 6.2
Cytokines in the sera of mice were assayed by ELISA on day 12 after immunization with MOG35-55 peptide. 1 d before immunization, groups of
mice were injected with control mAb (control) or with anti-NK1.1 (anti-NK1.1). Data represent mean 6 SD of the values (pg/ml) from four mice. IL-2
and IL-10 were not detected in the experiments. Statistical difference between control mAb and anti-NK1.1 mAb treatment was evaluated, and
indicated by * (P ,0.001) or ‡ (P ,0.0001).
MOG35-55, the LN cells from control mAb– (control) or anti-NK1.1 mAb–
treated (anti-NK1.1) B6 or b2m2/2 mice were cultured for 40 h with
(MOG1) or without MOG35-55 (MOG2) and the supernatants were col-
lected for measurement of IFN-g, IL-2, IL-4, and IL-10 by ELISA. Al-
though IL-2, IL-4, and IL-10 were not detectable in this experimental
setting, significant production of IFM-g was measured as shown here.
Data represent mean 6 SD of the mean value obtained by duplicate assays
in four independent experiments.1683 Zhang et al.
mAb showed no ameliorating effects (Fig. 8 D). These results
indicate that NK cells of RAG-22/2 mice play a regulatory
role, whereas non–NK cells from the mutant strain do not.
In additional experiments, 5 3 105 of ZB-1 line cells were
transferred into wild-type or b2m2/2 mice that had been
pretreated with anti-NK1.1 mAb (4 mice/group). None of
the mice developed EAE, contrasting the fatal outcome
seen in RAG-22/2 mice. This indicates that RAG-22/2
mice are more dependent on NK cells than wild-type or
b2m2/2 in the protection against passive EAE. Taken to-
gether, we conclude that NK cells can inhibit the effector
phase of EAE in a manner independent of T, B, or NK–T
cells.
Inhibition of T Cell Proliferation by NK Cells. To obtain
insights into the mechanism of NK cell–mediated regulation,
we conducted in vitro experiments, assaying antigen-induced
proliferation of ZB-1 cells in the presence of irradiated
spleen cells as APCs. First, spleen cells from NK cell–deleted
mice were compared with those from control mice as ac-
cessory cells for ZB-1 line cells. The experiment showed
that antigen-induced ZB-1 cell proliferation is enhanced
when spleen cells were derived from NK-deleted mice.
We obtained similar results not only with spleen cells from
wild-type B6 mice, but also from b2m2/2 mice (Fig. 9, A
and  B). These indicate that irradiated, spleen NK cells
would inhibit antigen-induced Th1 proliferation. Notably,
the proliferative responses obtained by using different sources
of spleen APCs roughly correlated with clinical grade of
Figure 7. Effect of NK cell deletion on passive EAE in b2m2/2 mice. After activation with MOG35-55 for 3 d, ZB-1 line cells (107) were intravenously
transferred into b2m2/2 mice pretreated on day 21 with control mAb (A) or with anti-NK1.1 mAb (B). The mice had been x irradiated (450 rad)
shortly before cell transfer, and received 500 ng of PT immediately after cell transfer.
Figure 6. Effect of NK cell deletion on passive EAE in wild-type B6
mice. After activation with MOG35-55 for 3 d, ZB-1 line cells (3 3 106)
were intravenously transferred into wild-type B6 mice pretreated on day
21 with control mAb (A) or with anti-NK1.1 mAb (B). The mice had
been x irradiated (450 rad) shortly before cell transfer, and received 500
ng of PT immediately after cell transfer.1684 Regulation of Autoimmune Encephalomyelitis by Natural Killer Cells
EAE and Th1 cytokine levels in the sera (Table 2), sup-
porting the relevance of the in vitro system for estimating
in vivo conditions.
We next examined the effect of insolubilized anti-NK1.1
mAb which can trigger activation of NK cells via cross-
linking NKR-P1 molecule (37). In a reciprocal manner
with the results in Fig. 9, ZB-1 cell proliferation in re-
sponse to MOG was significantly inhibited when spleen
NK cells were stimulated by anti-NK1.1 mAb (Fig. 10 A).
In contrast, insolubilized control mAb had no effect, fur-
ther supporting the inhibitory role of NK cells against T
cell proliferation. The background proliferation of ZB-1
cells was not inhibited by insolubilized anti-NK1.1 (Fig. 10
B). We also explored the possible involvement of IFN-g as
a downregulatory factor, since this Th1 cytokine is the ma-
jor product of NK cells. However, with the addition of ex-
ogenous IFN-g, the proliferation of ZB-1 line cells was
slightly but significantly enhanced (Fig. 10 C), whereas anti–
IFN-g mAb inhibited the cell proliferation (Fig. 10 D). In
addition, depressed proliferative response induced by insol-
ubilized anti-NK1.1 mAb was further inhibited by anti–
IFN-g mAb (data not shown). These results indicate that
NK cell–mediated T cell suppression is not mediated by
IFN-g.
Cytotoxic killing of B7-11 macrophages has been sug-
gested as a mechanism for regulation by NK cells (12, 38).
We have not yet excluded the possibility that NK cell–
mediated suppression of ZB-1 line cells may arise from cy-
totoxic killing of B7-11 APCs by NK cells. However, we
feel that this is not very likely because the NK/target cell
ratio in the assay condition is far from an optimal one, and
the number of B7-11 cells in the spleen or LNs did not de-
crease in mice deprived of NK cells and then challenged for
EAE. Furthermore, we recently found that T cell prolifera-
tion independent of antigen presentation process (recombi-
nant IFN-g or anti-CD3 mAb triggered T cell prolifera-
tion) can also be inhibited by NK cells. Experiments are
now in progress to analyze the interaction between NK cells
and encephalitogenic T cells.
Concluding Remarks. The present study demonstrates
Figure 8. Effect of NK cell deletion on passive EAE in RAG-22/2 mice and the treatment with spleen cells. 5 3 105 of activated ZB-1 line cells were
intravenously transferred into (A) RAG-22/2 mice pretreated on day 21 with control mAb (A) or with anti-NK1.1 mAb (B, C, and D). The mice were
injected with 500 ng PT after cell transfer. Although mice in B did not receive any further manipulation, 2 3 107 of spleen cells from RAG-22/2 mice
were intravenously transferred to mice in C on day 2 and the same number of spleen cells from RAG-22/2 mice which had been pretreated with anti-
NK1.1 mAb on day 21, were intravenously transferred to mice in D. This is a representative of two experiments with similar results.1685 Zhang et al.
Figure 9. Effect of NK cell deletion on antigen-induced proliferation of T line cells. ZB-1 T line cells (4 3 104 cells/well) were stimulated with
MOG35-55 in the presence of x irradiated spleen cells (8 3 105 cells/well) from wild-type B6 (A) or b2m2/2 mice (B). In each experiment, spleen cells
from mice pretreated with control mAb (control) and those pretreated with anti-NK1.1 mAb (anti-NK1.1) were compared in their accessory function.
Data represent mean cpm 6 SD of triplicate cultures. This is a representative of three experiments with similar results.
Figure 10. Effect of insolubilized anti-NK1.1 mAb, IFN-g, and anti–IFN-g on ZB-1 line proliferation. (A) Anti-NK1.1 and control M-11 mAb dis-
solved in PBS were added into relevant wells at various concentrations (shown in micrograms per milliliter), incubated overnight, and then washed with
PBS intensively. ZB-1 line cells (4 3 104/well) were stimulated with MOG35-55 (25 mg/ml) in the presence of irradiated spleen APCs (8 3 105/well) in
the wells coated with M-11 (ins. M11) or with anti-NK1.1 mAb (ins.NK1.1). (B) ZB-1 line cells were cultured with spleen cell APCs in the absence of
the MOG peptide in the antibody-coated wells in parallel with experiment A. (C) ZB-1 line cells were stimulated with MOG35-55 using spleen APCs in
the presence of different concentrations of recombinant mouse IFN-g (PharMingen). (D) ZB-1 line cells were stimulated with MOG35-55 using spleen
APCs in the presence of different concentrations of anti–mouse IFN-g mAb (PharMingen). All the data represent mean cpm 6 SD of triplicate cultures.1686 Regulation of Autoimmune Encephalomyelitis by Natural Killer Cells
that NK cells are involved in the regulation of EAE. Using
b2m2/2 mice, we proved that NK cells can regulate EAE
in a manner independent of NK–T cells. The function of
NK cells in immune response sometimes depends on other
immune elements such as CD81 T cells (39). However, us-
ing induced mutants, we excluded the requirement of other
populations such as CD81 T cells in the NK cell–mediated
regulation of EAE. We also indicated that the gene knock-
out mice for b2m and RAG-2 can be more susceptible to
EAE, particularly when NK cells are deleted. This raises a
possibility that depression of NK activity to the degree that
would have little effect on otherwise healthy individuals, may
lead to enhancement or induction of autoimmune disease
in those with a defect in the regulatory system.
In summary, we show how NK cells are deeply involved in
the resistance against EAE, a representative Th1-mediated
autoimmune disease. Although NK cells collaborate with
adaptive immunity and enhance Th1 immunity through
producing IFN-g in the protection against microbes (40–
42), they would rather inhibit Th1 activity in the protec-
tion against autoimmune disease. Functions of NK cells are
modulated by a number of endogenous and exogenous
stimuli, and modulation of NK function has been suggested
in autoimmune diseases such as multiple sclerosis (43). Fur-
ther studies on the regulatory interaction between NK and
T cells may lead to identification of key molecules involved
in the regulation of autoimmune diseases.
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